Tonix Pharmaceuticals Scores Key U.S. Patent For New Migraine Treatment Delivery Method

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company with a range of products and a robust pipeline, has announced that it has been granted U.S. Patent No. 12,090,139 by the United States Patent and Trademark Office on September 17, 2024. This patent covers "Formulations Comprising Triptan Compounds" and includes claims related to a pharmaceutical composition, a method for treating migraines through intranasal delivery, and an intranasal system specifically for Tosymra®. The patent is set to remain in effect until 2030, barring any potential extensions.

Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, said “We believe this patent further solidifies Tosymra® in the market as a differentiated drug with a differentiated administration method. This new patent targets specific delivery and composition. We are thrilled to have these additional issued patent claims, which add to the intellectual property protection existing for Tosymra®.”

In the U.S., close to 40 million individuals are affected by migraines, which is also identified as the second most common cause of disability globally. Migraines are marked by intense and debilitating episodes lasting from four to 72 hours. These attacks often involve throbbing headaches of moderate to severe pain, accompanied by symptoms such as nausea, vomiting, and heightened sensitivity to both light (photophobia) and sound (phonophobia).